Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 81 | 67 | |
1994 | Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid | KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 16 | 0 | |
2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
2017 | Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: A nationwide case-crossover study | Wen Y.-C.; FEI-YUAN HSIAO ; KIN-WEI CHAN ; Lin Z.-F.; LI-JIUAN SHEN ; CHENG-CHUNG FANG | Journal of Infectious Diseases | 45 | 37 | |
2013 | ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers | Liu W.-H.; Chen C.-H.; KUN-HUEI YEH ; Li C.-L.; Wu Y.-J.; DING-SHINN CHEN ; PEI-JER CHEN ; Shiou-Hwei Yeh | PLoS ONE | 24 | 18 | |
2008 | Adenoid cystic carcinoma of the breast arising in a lipoma mimicking hamartoma: Imaging manifestations and review of the literature | Kuo P.-H.; CHIUN-SHENG HUANG ; Huang W.-C.; SUNG-HSIN KUO ; JANE WANG | Chinese Journal of Radiology | 2 | | |
2018 | Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI | Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok T.S.K; CHIH-HSIN YANG ; Hoyle C. | Clinical Drug Investigation | 15 | 14 | |
2019 | Adjuvant radiotherapy for dermatofibrosarcoma protuberans: a case report | Hu, Ming Yuan; SUNG-HSIN KUO | Therapeutic Radiology and Oncology | 0 | 0 | |
2021 | Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives | Su Y.-Y.; CHIA-CHEN LI ; Lin Y.-J.; CHIUN HSU | Seminars in Liver Disease | 12 | 11 | |
2015 | Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis | CHIA-LIN HSU ; JEN-HAU CHEN ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Geriatric Oncology | 35 | 34 | |
2015 | Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) | Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H. | Ann. Oncol. | | | |
2018 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials | Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG ; Paz-Ares L; Park K. | Clinical Lung Cancer | 53 | 41 | |
2016 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial | Schuler M; CHIH-HSIN YANG ; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators | Annals of Oncology | 118 | 110 | |
2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | CHIH-HSIN YANG ; JIN-YUAN SHIH ; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG ; Miller V.A. | The Lancet Oncology | 383 | 337 | |
2022 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report | CHIH-HSIN YANG ; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Park, Keunchil; Passaro, Antonio; De Marinis, Filippo; Solca, Flavio; Märten, Angela; Kim, Edward S | Frontiers in oncology | 23 | 20 | |
2020 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | CHIH-HSIN YANG ; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; Märten A.; Kim E.S. | Journal of Thoracic Oncology | 175 | 156 | |
2014 | Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis | Popat S; Mok T; CHIH-HSIN YANG ; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. | Lung Cancer | 46 | 44 | |
2019 | Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations | SHENG-KAI LIANG ; JEN-CHUNG KO ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Lung Cancer | 27 | 25 | |
2015 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials | CHIH-HSIN YANG ; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. | The Lancet Oncology | 1318 | 1236 | |
2016 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial | Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. | The Lancet Oncology | 931 | 827 | |